Anhui Fengyuan Pharmaceutical Co., Ltd.

000153.SZ

000153.SZAnhui Fengyuan Pharmaceutical Co., Ltd. CN flag

Shenzhen

6.79

CNY

- -

0.35EPS

19.40P/E

3.16BMarket Cap

May 22Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Anhui Fengyuan Pharmaceutical Co., Ltd.

000153.SZ

(Shenzhen)

Recent

price

6.79

P/E

ratio

19.4

div

yld

2.21%

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 12/09

Stock

S&P500

-3.41

31.12

-21.41

29.89

51.90

92.99

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
2.2	2.67	2.95	4.18	4.55	3.65	3.89	3.59	4.65	5.89	6.79	7.4	7.6	8.36	9.02	9.2	9.28	Revenue per Share
0.04	0.06	0.11	0.03	0.05	0.07	0.09	0.08	0.1	0.15	0.14	0.18	0.24	0.28	0.35	0.34	0.35	Basic EPS, GAAP
0.05	-0.12	-0.1	-0.04	-0.14	-0.44	-0.38	0.02	0.13	0.01	0.34	-0.18	0.23	0.24	0.81	0.22	-0.37	Free Cash Flow per Basic Share
0.05	0.05	0.04	0.04	0.06	0.12	0.07	0.07	0.14	0.08	0.07	0.12	0.09	0.06	0.13	0.14	0.17	Dividend per Share
0.95	1.12	1.21	1.16	1.21	1.17	1.21	1.25	1.28	1.44	1.55	1.67	1.9	2.19	2.47	2.63	3.12	Book Value per Share
1.45	1.68	1.63	1.61	1.63	2.24	2.2	2.32	2.29	2.45	2.51	2.62	2.81	3.52	3.38	3.5	3.71	Tangible Book Value per Share
397	358	364	364	364	419	437	437	437	438	444	438	437	437	444	465	465	Basic Weighted Avg Shares
874	956	1,074	1,521	1,658	1,530	1,699	1,569	2,034	2,578	3,013	3,238	3,321	3,652	4,004	4,275	4,313	Sales/Revenue/Turnover
4.21	3.53	3.98	1.37	2.24	3.35	3.87	4.1	4.52	5.16	4.61	4.86	4.85	5.52	5.8	5.66	5.57	Operating Margin (%)
41	45	50	51	52	59	69	64	69	75	75	71	71	115	122	126	- -	Depreciation Expense
14	23	42	11	19	27	41	35	46	65	61	81	104	123	154	159	164	Net Income, GAAP
26.2	26.18	23.01	26.02	28.45	33.93	27.09	25.31	31.32	32.41	34.79	32.79	26.08	26.26	25.38	26.8	23.59	Effective Tax Rate (%)
1.62	2.41	3.88	0.72	1.15	1.79	2.41	2.24	2.25	2.53	2.02	2.5	3.12	3.37	3.86	3.73	3.81	Profit Margin (%)
54	121	68	9	10	266	9	-26	-71	6	-52	-296	-363	-70	-267	-111	-144	Working Capital
1	70	40	- -	60	197	68	59	43	- -	- -	105	65	115	190	195	226	LT Debt
654	679	754	764	775	1,120	1,147	1,199	1,153	1,220	1,292	1,327	1,448	1,771	1,755	1,919	2,022	Total Equity
3.28	2.77	3.37	1.54	2.52	2.52	2.95	2.81	3.6	5.13	5.27	5.83	5.8	6.49	6.91	6.77	6.54	Return on Invested Capital (%)
4.65	5.46	7.49	3.13	4.5	4.62	6.13	5.36	5.77	7.68	7.41	8.89	9.38	9.95	10.36	9.67	8.85	Return on Capital (%)
3.82	5.9	9.91	2.55	4.41	5.89	8.05	6.55	8.31	11	9.25	11.42	13.29	13.77	15.05	13.75	12.36	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	11.31%	7.28%	6.78%
Net Income, GAAP	21.01%	21.66%	3.15%
Free Cash Flow	330.24%	-41.7%	-71.35%
Total Cash Common Dividend	13.91%	27.27%	11.65%
Total Equity	5.74%	8.51%	9.35%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Similar Companies: Full Alliance Group, Inc. (FAGI)
Aequus Pharmaceuticals Inc. (AQSZF)
Ipca Laboratories Limited (IPCALAB.NS)
ViaDerma, Inc. (VDRM)
Abattis Bioceuticals Corp. (ATTBF)
Parenteral Drugs (India) Limited (PDPL.NS)
Business: Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biological pharmacy, chemical pharmacy, and traditional Chinese medicines primarily in China. It offers antipyretic-analgesic, cardiovascular, antibiotic, nervous system, anti-tumor, antiulcer, and hormone drugs, as well as nutraceuticals. The company also provides general medicines for vitamin and mineral deficiency; medicines for resisting parasitic diseases and microorganisms; coenzymes; and antiviral and uterine contractive medicines. In addition, it offers sedative-hypnotic drugs; drugs for curing mesenteric stress syndrome; drugs for lowering blood pressure; and drugs for curing benign prostatic hyperplasia. The company also exports its products to Europe, North America, Africa, Southeast Asia, and Central Asia. Anhui Fengyuan Pharmaceutical Co., Ltd. was founded in 1997 and is based in Hefei, China.

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
2.2	2.67	2.95	4.18	4.55	3.65	3.89	3.59	4.65	5.89	6.79	7.4	7.6	8.36	9.02	9.2	9.28	Revenue per Share
0.04	0.06	0.11	0.03	0.05	0.07	0.09	0.08	0.1	0.15	0.14	0.18	0.24	0.28	0.35	0.34	0.35	Basic EPS, GAAP
0.05	-0.12	-0.1	-0.04	-0.14	-0.44	-0.38	0.02	0.13	0.01	0.34	-0.18	0.23	0.24	0.81	0.22	-0.37	Free Cash Flow per Basic Share
0.05	0.05	0.04	0.04	0.06	0.12	0.07	0.07	0.14	0.08	0.07	0.12	0.09	0.06	0.13	0.14	0.17	Dividend per Share
0.95	1.12	1.21	1.16	1.21	1.17	1.21	1.25	1.28	1.44	1.55	1.67	1.9	2.19	2.47	2.63	3.12	Book Value per Share
1.45	1.68	1.63	1.61	1.63	2.24	2.2	2.32	2.29	2.45	2.51	2.62	2.81	3.52	3.38	3.5	3.71	Tangible Book Value per Share
397	358	364	364	364	419	437	437	437	438	444	438	437	437	444	465	465	Basic Weighted Avg Shares
874	956	1,074	1,521	1,658	1,530	1,699	1,569	2,034	2,578	3,013	3,238	3,321	3,652	4,004	4,275	4,313	Sales/Revenue/Turnover
4.21	3.53	3.98	1.37	2.24	3.35	3.87	4.1	4.52	5.16	4.61	4.86	4.85	5.52	5.8	5.66	5.57	Operating Margin (%)
41	45	50	51	52	59	69	64	69	75	75	71	71	115	122	126	- -	Depreciation Expense
14	23	42	11	19	27	41	35	46	65	61	81	104	123	154	159	164	Net Income, GAAP
26.2	26.18	23.01	26.02	28.45	33.93	27.09	25.31	31.32	32.41	34.79	32.79	26.08	26.26	25.38	26.8	23.59	Effective Tax Rate (%)
1.62	2.41	3.88	0.72	1.15	1.79	2.41	2.24	2.25	2.53	2.02	2.5	3.12	3.37	3.86	3.73	3.81	Profit Margin (%)
54	121	68	9	10	266	9	-26	-71	6	-52	-296	-363	-70	-267	-111	-144	Working Capital
1	70	40	- -	60	197	68	59	43	- -	- -	105	65	115	190	195	226	LT Debt
654	679	754	764	775	1,120	1,147	1,199	1,153	1,220	1,292	1,327	1,448	1,771	1,755	1,919	2,022	Total Equity
3.28	2.77	3.37	1.54	2.52	2.52	2.95	2.81	3.6	5.13	5.27	5.83	5.8	6.49	6.91	6.77	6.54	Return on Invested Capital (%)
4.65	5.46	7.49	3.13	4.5	4.62	6.13	5.36	5.77	7.68	7.41	8.89	9.38	9.95	10.36	9.67	8.85	Return on Capital (%)
3.82	5.9	9.91	2.55	4.41	5.89	8.05	6.55	8.31	11	9.25	11.42	13.29	13.77	15.05	13.75	12.36	Return on Common Equity (%)

	Mar'24	Jun'24	Sep'24
Total Current Assets	2,124	2,124	2,015
Accounts Receivable, Net	1,026	1,113	1,022
Cash, Cash Equivalents & STI	336	252	241
Inventories	569	570	579
Total Current Liabilities	- -	2,263	2,159
Payables & Accruals	- -	- -	- -
ST Debt	629	632	653
Deferred Revenue	- -	- -	- -

	Mar'24	Jun'24	Sep'24
ST Debt	629	632	653
LT Borrowings	199	203	211
LT Finance Leases	20	16	15
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	465	465	465
Market Capitalization	3,616	2,538	2,845

Year	Q1	Q2	Q3	Q4	FY
2022	988	935	968	1,139	4,004
2023	1,206	1,079	939	1,051	4,275
2024	1,121	1,187	954	- -	- -

Anhui Fengyuan Pharmaceutical Co., Ltd.

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year